Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation

International Journal of Hematology

Volumn 88, Issue 5, 2009, Pages 588-595

  Hiramatsu, Yasushi ^a   Maeda, Yoshinobu ^a   Fujii, Nobuharu ^a   Saito, Takashi ^b   Nawa, Yuichiro ^c   Hara, Masamichi ^c   Yano, Tomofumi ^d   Asakura, Shoji ^e   Sunami, Kazutaka ^e   Tabayashi, Takayuki ^f   Miyata, Akira ^f   Matsuoka, Ken Ichi ^a   Shinagawa, Katsuji ^a   Ikeda, Kazuma ^a   Matsuo, Keitaro ^g   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d Japan Labour Health and Welfare Organization   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION   (Japan)

^f CHUGOKU CENTRAL HOSPITAL   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Antifungal prophylaxis; Hematopoietic stem cell transplantation; Micafungin

Indexed keywords

CYCLOSPORIN; FLUCONAZOLE; MICAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPERGILLUS FUMIGATUS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER DISEASE; LUNG ASPERGILLOSIS; MALE; MYCOSIS; NEUTROPENIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT DISEASE; ALLOTRANSPLANTATION; BLOOD DISEASE; COMPARATIVE STUDY; MIDDLE AGED; MULTICENTER STUDY;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIPOPEPTIDES; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; PROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 64249152006     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0196-y     Document Type: Article

References (23)

1. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000;6:659-713; 5; 7-27; quiz 29-33.
2. JL Goodman DJ Winston RA Greenfield PH Chandrasekar B Fox H Kaizer 1992 A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation N Engl J Med 326 845 51
3. MA Slavin B Osborne R Adams MJ Levenstein HG Schoch AR Feldman 1995 Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study J Infect Dis 171 1545 52
4. JH van Burik W Leisenring D Myerson RC Hackman HM Shulman GE Sale 1998 The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients Medicine (Baltimore) 77 246 54 10.1097/00005792-199807000-00003
5. L Hovi UM Saarinen-Pihkala K Vettenranta H Saxen 2000 Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years Bone Marrow Transplant 26 999 1004 10.1038/sj.bmt.1702654
6. TJ Walsh 2002 Echinocandins-an advance in the primary treatment of invasive candidiasis N Engl J Med 347 2070 2 10.1056/NEJMe020142
7. NH Georgopapadakou 2001 Update on antifungals targeted to the cell wall: focus on beta-1, 3-glucan synthase inhibitors Expert Opin Invest Drugs 10 269 80 10.1517/13543784.10.2.269
8. V Petraitis R Petraitiene AH Groll K Roussillon M Hemmings CA Lyman 2002 Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits Antimicrob Agents Chemother 46 1857 69 10.1128/AAC.46.6.1857-1869.2002
9. JA van Burik V Ratanatharathorn DE Stepan CB Miller JH Lipton DH Vesole 2004 Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation Clin Infect Dis 39 1407 16 10.1086/422312
10. S Hashino L Morita M Takahata M Onozawa M Nakagawa T Kawamura 2008 Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation Int J Hematol 87 91 7 10.1007/s12185-007-0011-1
11. N de Wet A Llanos-Cuentas J Suleiman E Baraldi EF Krantz M Della Negra 2004 A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients Clin Infect Dis 39 842 9 10.1086/423377
12. S Ascioglu JH Rex B de Pauw JE Bennett J Bille F Crokaert 2002 Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus Clin Infect Dis 34 7 14 10.1086/323335
13. NT de Wet AJ Bester JJ Viljoen F Filho JM Suleiman E Ticona 2005 A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis Aliment Pharmacol Ther 21 899 907 10.1111/j.1365-2036.2005.02427.x
14. K Pettengell J Mynhardt T Kluyts W Lau D Facklam D Buell 2004 Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent Aliment Pharmacol Ther 20 475 81 10.1111/j.1365-2036.2004.02083.x
15. K Hatano Y Morishita T Nakai F Ikeda 2002 Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus J Antibiot (Tokyo) 55 219 22
16. T Nakai J Uno K Otomo F Ikeda S Tawara T Goto 2002 In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds Chemotherapy 48 78 81 10.1159/000057666
17. B Sirohi RL Powles R Chopra N Russell JL Byrne HG Prentice 2006 A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation Bone Marrow Transplant 38 47 51 10.1038/sj.bmt.1705398
18. AH Saad DD DePestel PL Carver 2006 Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants Pharmacotherapy 26 1730 44 10.1592/phco.26.12.1730
19. T Sakaeda K Iwaki M Kakumoto M Nishikawa T Niwa JS Jin 2005 Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs J Pharm Pharmacol 57 759 64 10.1211/0022357056118
20. MF Hebert DK Blough RW Townsend M Allison D Buell J Keirns 2005 Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers J Clin Pharmacol 45 1018 24 10.1177/0091270005279274
21. S Tawara F Ikeda K Maki Y Morishita K Otomo N Teratani 2000 In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi Antimicrob Agents Chemother 44 57 62
22. K Matsue H Uryu M Koseki N Asada M Takeuchi 2006 Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin Clin Infect Dis 42 753 7 10.1086/500323
23. D Goodman E Pamer A Jakubowski C Morris K Sepkowitz 2002 Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate Clin Infect Dis 35 E35 6 10.1086/341305